

- encephalomyopathy-like syndrome after allogeneic haematopoietic stem cell transplantation. *BMJ Case Rep* 2017;2017.
102. Sicurelli F, Carluccio MA, Toraldo F, Tozzi M, Bucalossi A, et al. Clinical and biochemical improvement following HSCT in a patient with MNGIE: 1-year follow-up. *J Neurol* 2012;259:1985-7.
 103. Naymagon S, Naymagon L, Wong SY, Ko HM, Renteria A, et al. Acute graft-versus-host disease of the gut: considerations for the gastroenterologist. *Nat Rev Gastroenterol Hepatol* 2017;14:711-26.
 104. D'Angelo R, Rinaldi R, Pironi L, Dotti MT, Pinna AD, et al. Liver transplant reverses biochemical imbalance in mitochondrial neurogastrointestinal encephalomyopathy. *Mitochondrion* 2017;34:101-2.
 105. Boschetti E, D'Alessandro R, Bianco F, Carelli V, Cenacchi G, et al. Liver as a source for thymidine phosphorylase replacement in mitochondrial neurogastrointestinal encephalomyopathy. *PLoS One* 2014;9:e96692.
 106. Madhok J, Leong J, Cohn J. Anesthetic considerations for liver transplantation in a patient with mitochondrial neurogastrointestinal encephalopathy syndrome. *Cureus* 2019;11:e5038.
 107. De Vocht C, Ranquin A, Willaert R, Van Ginderachter JA, Vanhaecke T, et al. Assessment of stability, toxicity and immunogenicity of new polymeric nanoreactors for use in enzyme replacement therapy of MNGIE. *J Control Release* 2009;137:246-54.
 108. López LC, Akman HO, García-Cazorla A, Dorado B, Martí R, et al. Unbalanced deoxynucleotide pools cause mitochondrial DNA instability in thymidine phosphorylase-deficient mice. *2009;18:714-22.*
 109. Torres-Torronteras J, Gómez A, Eixarch H, Palenzuela L, Pizzorno G, et al. Hematopoietic gene therapy restores thymidine phosphorylase activity in a cell culture and a murine model of MNGIE. *Gene Ther* 2011;18:795-806.
 110. Torres-Torronteras J, Cabrera-Pérez R, Barba I, Costa C, de Luna N, et al. Long-term restoration of thymidine phosphorylase function and nucleoside homeostasis using hematopoietic gene therapy in a murine model of mitochondrial neurogastrointestinal encephalomyopathy. *Hum Gene Ther* 2016;27:656-67.
 111. Yadak R, Boot M V., Van Til NP, Cazals-Hatem D, Finkenstedt A, et al. Transplantation, gene therapy and intestinal pathology in MNGIE patients and mice. *BMC Gastroenterol* 2018;18:149.
 112. Torres-Torronteras J, Viscomi C, Cabrera-Pérez R, Cámara Y, Di Meo I, et al. Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE. *Mol Ther* 2014;22:901-7.
 113. Torres-Torronteras J, Cabrera-Pérez R, Vila-Julíà F, Viscomi C, Cámara Y, et al. Long-term sustained effect of liver-targeted adeno-associated virus gene therapy for mitochondrial neurogastrointestinal encephalomyopathy. *Hum Gene Ther* 2018;29:708-18.